ArticleAmerican journal of physiology. Renal physiology2015
Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury.
Article in American journal of physiology. Renal physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Research progress of nanoparticles in the diagnosis and treatment of renal ischemia-reperfusion injury.Journal of nanobiotechnology · 2026Review
- NovelMedical physics · 2025Article
- Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions.Journal of the American Society of Nephrology : JASN · 2025Review
- Targeted therapy of kidney disease with nanoparticle drug delivery materials.Bioactive materials · 2024Review
- Progress of nanomaterials in the treatment of thrombus.Drug delivery and translational research · 2024Review
- Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction.International journal of molecular sciences · 2023Article
- Review
- Protective role of antithrombin III in suppressing acute responses in a rat model of renal ischemia-reperfusion injury.Molecular and cellular biochemistry · 2022Article
- Sustained local inhibition of thrombin preserves renal microarchitecture and function after onset of acute kidney injury.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Functional Imaging Using Fluorine (Methods in molecular biology (Clifton, N.J.) · 2021Article
- Fluorine (Methods in molecular biology (Clifton, N.J.) · 2021Article
- Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Review
- Hirudin Protects Against Kidney Damage in Streptozotocin-Induced Diabetic Nephropathy Rats by Inhibiting Inflammation via P38 MAPK/NF-κB Pathway.Drug design, development and therapy · 2020Article
- Antithrombin Perfluorocarbon Nanoparticles Improve Renal Allograft Function in a Murine Deceased Criteria Donor Model.Transplantation direct · 2018Article
- Quantification of vascular damage in acute kidney injury with fluorine magnetic resonance imaging and spectroscopy.Magnetic resonance in medicine · 2018Article
- Application of Light Scattering Techniques to Nanoparticle Characterization and Development.Frontiers in chemistry · 2018Review
- Reducing Inflammatory Cytokine Production from Renal Collecting Duct Cells by Inhibiting GATA2 Ameliorates Acute Kidney Injury.Molecular and cellular biology · 2017Article
- The Future of Nanoparticle-Directed Venous Therapy.Seminars in interventional radiology · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
In the extension phase of acute kidney injury, microvascular thrombosis, inflammation, vasoconstriction, and vascular endothelial cell dysfunction promote progressive damage to renal parenchyma after reperfusion. In this study, we hypothesized that direct targeting and pharmaceutical knockdown of activated thrombin at the sites of injury with a selective nanoparticle (NP)-based thrombin inhibitor, PPACK (phenylalanine-proline-arginine-chloromethylketone), would improve kidney reperfusion and protect renal function after transient warm ischemia in rodent models. Saline- or plain NP-treated animals were employed as controls. In vivo 19F magnetic resonance imaging revealed that kidney nonreperfusion was evident within 3 h after global kidney reperfusion at 34 ± 13% area in the saline group and 43 ± 12% area in the plain NP group and substantially reduced to 17 ± 4% (∼50% decrease, P < 0.05) in the PPACK NP pretreatment group. PPACK NP pretreatment prevented an increase in serum creatinine concentration within 24 h after ischemia-reperfusion, reflecting preserved renal function. Histologic analysis illustrated substantially reduced intrarenal thrombin accumulation within 24 h after reperfusion for PPACK NP-treated kidneys (0.11% ± 0.06%) compared with saline-treated kidneys (0.58 ± 0.37%). These results suggest a direct role for thrombin in the pathophysiology of AKI and a nanomedicine-based preventative strategy for improving kidney reperfusion after transient warm ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.